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Mycophenolate mofetil treatment for primary glomerular dis- nephrotic proteinuria could be achieved in patients with
eases. relapsing minimal change disease, membranous nephrop-
Background. Treatment of primary glomerular diseases may athy, and lupus nephritis [1]. Since that time, several ad-be unsuccessful or have potential toxicities. Therefore, we eval-
ditional reports have been published about the clinicaluated the use of mycophenolate mofetil (MMF) for empirical
efficacy of MMF for the treatment of lupus nephritistreatment of primary glomerulopathies.
Methods. Forty-six patients with biopsy-proven primary glo- [2–4]. In addition, an increasing number of publications
merulopathies received MMF for 3 months as adjunctive or have reported favorable responses of various experimen-
primary treatment. Median (range) 24-hour urine protein to cre- tal models of glomerular diseases to MMF [5–15], and
atinine ratio (Up/c) and serum creatinine at the start and end several additional reports have indicated the clinical ef-of MMF therapy were compared using the Wilcoxon signed-
ficacy in some patients with primary glomerulopathiesranks test.
Results. Overall, the median Up/c decreased from 4.7 (range [16–18] and pauci-immune necrotizing glomeruloneph-
0.1, 20.3) to 1.1 (0.1, 14.3; P  0.001) at the end of MMF ritis (abstracts; Heering et al, J Am Soc Nephrol 9:
treatment with no significant change in median serum creati- 456A-7A, 1998; Wen-Ling et al, J Am Soc Nephrol, 9:
nine 1.3 (0.6 to 6.1) to 1.2 (0.5 to 6.5) mg/dL. Median serum
496A, 1998; Radhakrishnan et al, J Am Soc Nephrol 10:albumin increased from 3.4 (1.4, 4.6) to 4.1 (1.7, 48) g/dL (P 
114A, 1999) [19].0.001) and the median serum cholesterol decreased from 270
(148, 795) to 220 (140, 309) mg/dL (P 0.001) post-treatment. The purpose of this study was to determine the efficacy
For those with minimal change disease, a complete steroid of MMF in the empiric treatment of a group of 46 pa-
withdrawal was accomplished in 5/6 steroid dependent patients. tients with primary glomerular disease, including inter-
Focal segmental glomerulosclerosis (FSGS) patients had a me-
mediate-term follow-up for five (non-lupus) of the pa-dian Up/c that decreased from 2.7 (0.1, 20.3) to 0.8 (0.1, 8.2;
tients in our earlier report [1].P  0.001) in 18 patients. In membranous nephropathy (MN)
patients, the median Up/c decreased from 7.3 (0.1, 18.5) to 1.5
(0.1, 14.3) (P 0.001) in 17 patients. No significant change in
METHODSmedian serum creatinine was detected in FSGS or MN patient
groups during treatment. Study population
Conclusions. Empirical MMF therapy in the majority of pa-
The study population consisted of patients who at-tients with primary glomerulopathies was well tolerated and
achieved the goals of steroid withdrawal, improvement of ne- tended the outpatient nephrology treatment of a large
phrotic syndrome, and stabilization of renal function. tertiary referral hospital between 1996 and 1999, who
had biopsy proven glomerulonephritis complicated by
nephrotic syndrome and/or renal insufficiency, and who
Our initial report of treatment of seven patients with received at least three months of treatment with MMF.
various glomerular diseases with mycophenolate mofetil Patients with secondary forms of glomerulonephritis, such
(MMF) showed that partial or complete remissions of as secondary FSGS from hyperfiltration injury (for exam-
ple, sickle cell disease) were excluded from this analysis.
The most frequent indications for the utilization of MMFKey words: mycophenolate mofetil, nephrotic syndrome, focal segmen-
as adjunctive (or sometimes primary) treatment of thesetal glomerulosclerosis, minimal change disease, membranous nephrop-
athy, renal insufficiency. patients included steroid-resistant (19.7%) or steroid-
dependent nephrotic syndrome (32.6%). Other indi-Received for publication February 21, 2001
cations included cyclosporine (CsA)-resistant or CsA-and in revised form October 18, 2001
Accepted for publication October 19, 2001 dependent nephrotic syndrome or serious side effects
from or intolerance of steroid or CsA; azathioprine (AZA) 2002 by the International Society of Nephrology
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dependence; deteriorating renal function; a patient’s re- receiving either therapy, the ACEi or AIIRa had been
discontinued because of intolerance. In hypertensive pa-fusal of steroid treatment; and relapses in progressive
renal insufficiency with efforts to discontinue cyclophos- tients, one or more antihypertensive agents were pre-
scribed and the dosage titrated in an attempt to achievephamide (CTX).
blood pressures 130/80 mm Hg. All patients were ad-
Treatment regimen vised regarding appropriate dietary restrictions including
a low sodium (2 g/day) diet. No attempt was made toAll patients were counseled regarding the unproven
efficacy and unknown long-term side effects of MMF pursue an aggressive protein restricted diet.
therapy. This was a retrospective analysis of our clinical
Follow-uppractice performed without a formal protocol, and there-
fore Institutional Review Board (IRB) approval was not Clinical and laboratory parameters were monitored
on a monthly basis for the initial three to six months ofobtained. In the majority of patients, MMF was initiated
at 0.5 to 0.75 g BID and advanced as appropriate or as MMF treatment, then at variable intervals thereafter.
Laboratory parameters included complete blood counttolerated to 0.5 g TID or 1.0 g BID, with one patient
receiving 1.5 g BID. Given the reported alterations in (CBC), serum creatinine (SCr), blood urea nitrogen (BUN),
albumin, non-fasting cholesterol, and aspartate amino-the pharmacokinetics of MMF and its metabolite, myco-
phenolic acid (MPA), in patients with marked reductions transferase (AST). Protein and creatinine excretion rates
were measured from spontaneously voided, non-super-in glomerular filtration rate, the dose was carefully ti-
trated and limited to 1.5 g or less daily in most patients vised, 24-hour urine collections or from ‘spot’ morning
urine samples (7.8% of measurements) when the formerwith advanced renal insufficiency. The MMF dose was
decreased by 25 to 33% for persistent or moderately could not be obtained. These latter samples were pro-
vided by the patient during the clinic visit and weresevere gastrointestinal symptoms. MMF was discon-
tinued temporarily if the total white blood cell (WBC) thus obtained at approximately the same time of day
throughout the study period. In order to avoid inaccura-decreased to 4000/L or if the patient developed a fe-
brile illness or unacceptable gastrointestinal symptoms. cies due to the under- or over-collection of the 24-hour
urine samples, proteinuria was adjusted for the concomi-It was discontinued permanently if hepatic enzymes in-
creased2 times the upper limits of normal without other tant creatinine excretion of results expressed as the urine
protein-to-creatinine ratio (Up/c). In addition, data oncause or if there developed evidence of malignancy.
The majority of patients (67%) received variable doses the use of ACEi/AIIRa and 3-hydroxy-methylglutaryl
coenzyme A (HMG CoA) reductase inhibitors was ab-of steroid concomitant with initiation of MMF therapy,
ranging from very low doses (such as, methylpredniso- stracted from the medical records, where there was a
definite comment regarding the use or non use of thelone 8 mg every other day) to high dose daily steroid or
a cyclic oral steroid minipulse strategy [1]. Oral methyl- medication type.
prednisolone (MP) minipulse therapy consisted of MP
Study end pointsadministration in four two-week cycles: 3 mg/kg/day 
3 days (maximum 240 mg/day and 2 mg/kg/day if age This study reports the outcome with the first consecu-
tive treatment course with MMF and provides additional60 year old) followed by a lower dose for the next 11
days (24 mg/day in cycle 1, 16 mg/day in cycle 2, 12 mg/ information regarding the subsequent clinical course.
The primary study outcomes were the change in the Up/cday in cycle 3, and 8 mg/day in cycle 4). In the absence
of relapse, this was followed by 8 mg qod  2 weeks ratio and serum creatinine, comparing the levels at the
start of MMF treatment with those at the end of theand then 4 mg qod  2 weeks and then discontinued.
In patients receiving other steroid regimens, an effort MMF treatment period. The end of MMF treatment was
defined as the completion of therapy or the latest datawas made to withdraw and, if possible, discontinue the
steroid over the initial three to four months of MMF available at the time of collation and analysis. For pro-
teinuria, a complete remission was defined as a reductiontherapy. Four patients were treated with CsA (#11, 26,
28, 32); one patient was treated with AZA and one with in Up/c to 0.3; a partial remission as a 50% or greater
reduction in Up/c, with a post-study Up/c of 0.3; stableCTX (#37) at the start of MMF therapy. Three patients
had short courses of overlapping CsA treatment for six proteinuria as a reduction of less than 50%, with a post-
study Up/c of 0.3; and a deterioration as any increaseweeks (#26) and two weeks (#11, #32). The CTX depen-
dent patient had a progressive reduction in dose as MMF in the Up/c over a baseline value that was 0.3. In addi-
tion, the proportion of patients with initial nephroticwas introduced over four weeks.
Twenty of the 46 patients were receiving either angio- range proteinuria (Up/c 2.5) whose proteinuria had de-
creased to the sub-nephrotic (Up/c 2.5) range by thetensin-converting enzyme inhibitor (ACEi) or angioten-
sin II receptor antagonist (AIIRa) therapy prior to initia- end of the follow-up is reported.
Responses in excretory renal function, in those pa-tion of MMF. In most of those patients who were not
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tients with renal insufficiency, were assessed based on age was 45.5 years (16.4), range 16 to 78 years. The
primary glomerular diseases represented included mini-changes in serum creatinine before and at the end of
treatment. Renal insufficiency was defined as a serum mal change disease (MCD) in 15.2%, focal segmental
glomerulosclerosis (FSGS) in 39.1%, membranous ne-creatinine 1.4 mg/dL for men and 1.2 mg/dL for wo-
men. A favorable response included either a 15% de- phropathy (MN) in 37%, and miscellaneous etiologies
in 8.7% [comprised of 3 patients with IgA nephropathycrease in serum creatinine or stabilization of the serum
creatinine in a patient with rapidly rising values prior to (IgAN), and 1 with membranoproliferative glomerulo-
nephritis (MPGN)]. At the time of study entry 31 pa-MMF treatment. Rapidly rising serum creatinine was
defined as a sustained increase 20% within 40 weeks tients (67.4%) had nephrotic range proteinuria and 23
(50%) had renal insufficiency. Baseline Up/c and serumprior to initiating MMF treatment. These patients had
a baseline serum creatinine of  2.5 mg/dL at the start creatinine were 4.7 (0.1 to 20.3) and 1.3 mg/dL (0.6
to 6.1), respectively. Overall, 67.4% were treated withof MMF therapy. This time period was selected after
review of dates when results were available, but before steroids in addition to MMF and 43% by an ACE inhibi-
tor (51% excluding the patients with MCD) prior toany comparative analysis was performed. Changes of
renal function were also estimated using the four-vari- initiating MMF. At the end of the treatment period, 23
of 46 (50%) were on ACEi (59% if MCD excluded).able simplified MDRD glomerular filtration rate (GFR)
equation (abstract; Levey, J Am Soc Nephrol 11:155A, The median (range) dose and duration of MMF therapy
was 2 g/day (0.75 to 3.00) and 8 months (3 to 26). The2000). This formula uses age, race, serum creatinine, and
sex to estimate GFR per 1.73 m2 and has been highly demographic, clinical, and treatment details of individual
patients, stratified by histopathologic diagnosis, are pro-correlated with GFR estimates using the original vali-
dated six variable (SCr, BUN, albumin, sex, age, race) vided in Table 1. Follow-up data on patients completing
a course of MMF is summarized in Table 2.equation used in the MDRD study [20].
For convenience, patients were defined as being on an The Up/c pre MMF treatment was 4.7 (0.1 to 20.3)
and decreased significantly to 1.1 (0.1 to 14.3) at theincreased dose of ACEi, AIIRa, or HMG CoA reductase
inhibitors if they either started the agent or increased end of the MMF treatment period (P  0.001; Fig. 1A).
Over the course of treatment, 7 patients (15.6%)—their dose of these medications during the course of the
study; a stable dose was defined as being on the same including 5 who were initially nephrotic—had a complete
remission of proteinuria, with a median percent reduc-dose or a clinically equivalent dose of a similar agent;
and a decrease in dose was defined as either stopping tion of 98%; 17 patients (37.8%)—including 15 nephrot-
ics—had a partial remission, with a median percent re-or reducing the dose of the agent during the course of
the study. duction of 74%, and 5 patients (11.1%)—including 2
nephrotics—had an increase in proteinuria. Sixteen of
Statistical analysis the 31 (51.6%) initially nephrotic patients improved to
having non-nephrotic range proteinuria by the end ofThe internal consistency of the data was assessed using
time trend analysis (identifying values which differed the study.
The serum albumin (N  39) increased significantlysubstantially from the previous recorded values) and us-
ing box plots to identify outlying values for a given distri- from 3.4 (1.4 to 4.6) g/dL pre-MMF to 4.1 (1.7 to 4.8)
g/dL (P  0.001; Fig. 1B). The serum cholesterol (N bution; the accuracy of the identified values was con-
firmed by comparison with the original clinical record. 29) decreased from 275 (168 to 795) mg/dL to 218 (140
to 309) mg/dL at the end of the MMF treatment periodWilcoxon signed-ranks test was used as appropriate to
compare data from the start and end of the treatment (P  0.001; Fig. 1C). The change in mean arterial pres-
sure (MAP; N  39) was 5.3 (32 to 19.3) mm Hgperiod, as defined above. In cases where there was in-
complete paired data, analysis was conducted on avail- (P  0.008). Similar significant changes were present for
the individual diastolic and systolic blood pressure (dataable data with the number of subjects included in the
analysis clearly stated. In all analyses a two-tailed type not shown).
As shown in Table 3, there was no significant changeI error rate of 0.05 was used. Analyses were performed
using SPSS Base 7.5 (SPSS, Inc., Cary, NC, USA) Values in the measured serum creatinine over the course of the
study. However, the overall GFR as estimated by 100are presented as median (range) unless otherwise stated.
multiplied by the reciprocal of serum creatinine or the
modified four-variable MDRD formula significantly in-
RESULTS
creased. Using the four-variable MDRD formula, GFR
Total study group increased from 59.4 (11.4, 191.0) mL/min/1.73 m2 to 67.3
(10.3, 191.0) mL/min/1.73 m2 (P  0.032; Fig. 1D andThis patient cohort was comprised of 18 women and
28 men, 78.3% were Caucasian, 17.4% African Ameri- Table 4). Renal insufficiency resolved in 4 of the 23
(17.4%) patients with renal insufficiency initially, 3 withcan, and 4.3% Asian. The mean (standard deviation)
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Table 2. Follow up data of patients completing MMF
Urine protein/creatinine Serum creatinine
(months on MMF) (months after MMF D/C)
Pre → Post .......................................... Latest Pre → Post .................. Latest
Pt # Relapse(	) Med 

Minimal change
(6) (2)
1 6.0 → CR ........................................ 2.0	 1.0 → 1.0 ................... 1.0
(26) (2)
2 6.0 → CR ........................................ CR 1.1 → 0.9 S
(6) (17)
3 4.6 → 2.8 ......................................... CR 0.8 → 0.8 MMF D/C
(6) (30)
4 2.4 → CR ........................................ CR 1.3 → 1.3 S
(11) (5)
5 0.1 → 0.1 ......................................... 0.1 1.0 → 0.7 S
(3) (13)
6 5.3 → 5.8 ......................................... CR 1.7 1.6 ................... 1.7 	T
FSGS
(11) (36)
8 2.0 → 2.1 ......................................... 1.8 2.5 → 2.6 ................... 4.3 S
(4) (8)
10 2.8 → 0.7 ......................................... CR 2.0 → 2.0 ................... 2.0
(11) (21)
11 0.6 → 0.4 ......................................... 3.4 1.2 → 1.1 S
(8) (11)
13 3.3 → CR ........................................ CR 1.7 → 0.9 ................... 0.8 S
(8) (9)
15 2.0 → CR 2.8 → 3.2 ................... 2.8
(13) (8)
17 20.3 → 4.9 ......................................... 2.4 1.7 → 2.3 ................... 2.4 S
(10) (6)
19 2.2 → 0.7 ......................................... 1.3 1.2 → 1.3 ................... 1.3 S
(6) (4)
20 1.7 → 1.7 ......................................... 3.0	 1.7 → 1.7 ................... 1.6 MMF D/C
(4) (15)
21 2.7 → 0.7 ......................................... 0.9 0.9 → 0.9 ................... 1.2 S
(10) (10) (2)
24 1.9 → 0.5 4.9 → 5.6 ................... 6.8
(5) (5) (0.5)
25 6.2 → 3.9 3.9 → 6.3 ................... 6.6 S
MN
(6) (9)
26 0.1 → 0.2 ......................................... 1.0	 1.0 → 1.0 ................... 1.0
(7) (3)
27 12.8 → 7.7 ......................................... 7.1	 3.5 → 1.7 ................... 1.8 MMF D/C
(13) (5)
28 7.3 → 1.2 ......................................... 0.8 1.1 → 1.2 ................... 1.5 MMF D/C
(18) (28)
30 4.0 → 1.2 ......................................... 1.8 0.8 → 0.6 ................... 0.8
(12) (24)
31 4.7 → CR ........................................ CR 0.8 → 0.5
(6) (2)
34 3.6 → 1.1 ......................................... 2.0	 0.7 → 0.7 ................... 0.7 S
(10) (1)
35 9.3 → CR ........................................ CR 1.1 → 1.1 S
(4) (6)
36 10.5 → 6.0 ......................................... 8.0	 2.9 → 2.8 ................... 3.5
(10) (10) (1)
38 12.3 → 5.4 1.8 → 1.7 ................... 2.2 S
(6) (24)
40 4.4 → 1.5 ......................................... CR 1.0 → 0.7 ................... 0.8
(7) (7) (12)
42 13.3 → 14.3 1.2 → 1.1 ................... 1.8
IgA/MPGN
(6) (3	)
43 6.3 → 1.2 ......................................... 1.0 3.9 → 2.3 ................... 3.4 S
(4) (4) (12)
45 0.1 → 0.1 1.8 → 1.5 ................... 1.7
(11) (11) (6)
46 4.9 → 3.9 2.2 → 2.2 ................... 1.6 MMF D/C
Follow up data on patients who completed a course of MMF therapy is provided. Urine protein creatinine ratios (Up/c) at the start and end of MMF therapy are
given between the arrows. Last follow-up is provided. After the ......, relapse is denoted first by the 	 sign. The number in the parentheses represents months of
MMF treatment, the number in the second parentheses represents months after MMF was discontinued. The serum creatinine (Scr) is shown in a similar fashion.
Numbers in the parentheses for SCr are only given if different from Up/c data. Medication changes are described as  if a medication is withdrawn, or 	 if active
MMF. D/C denotes adverse effect of MMF requiring withdrawal. Abbreviations are: Up/c, urine protein creatinine ratio; SCr, serum creatinine (mg/dL); , drug
withdrawal; 	, addition of medication; MMF D/C is noted for MMF withdrawal secondary to adverse reaction; S, steroids; T, Tacrolimus; CR, complete remission.
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Fig. 1. Median plus interquartile range of urine
protein-to-creatine ratio (Up/c), serum albumin,
and serum cholesterol and estimated glomeru-
lar filtration rate (GFR). (A) Median plus in-
terquartile range, pre- and post-mycopheno-
late mofetil (MMF) treatment, of the Up/c ratio
is shown for the entire study population. (B)
Median plus interquartile range of serum al-
bumin prior to and after MMF treatment of
the overall group is demonstrated. (C ) Me-
dian plus interquartile range pre- and post-
MMF treatment serum cholesterol for the
overall group is shown. (D) Median plus inter-
quartile range pre- and post-treatment GFR
as estimated by the modified four-variable
MDRD equation.
MN, 1 with FSGS; only 1 patient (who had IgA nephrop- the remission has been sustained following discontinua-
tion of the initial (and only) course of MMF. Patient #1athy) developed de novo renal insufficiency.
During the study period, 7 of 46 (15.2%) patients de- initially relapsed twice when MMF was stopped, re-
sponding again to MMF monotherapy; she was MMFcreased their ACEi/AIIRa use, 28 (60.9%) continued on
the same dose, and 11 (23.9%) increased their dose. With dependent for 30 months of MMF treatment before a
sustained remission was achieved. Complete withdrawalregards to lipid lowering therapy over follow-up, 4 of
29 patients (13.8%) decreased their dose, 17 (58.6%) of steroids was achieved in 5 of the 6 patients. Patient
#3 had a substantial partial remission (Up/c 4.6 → 0.6) byremained on a constant dose, and 8 (27.6%) increased
their dose. There was no significant difference between 3 months of MMF treatment, but relapsed with attempts
at steroid withdrawal. In addition, he presented with achanges in Up/c, SCr, blood pressure control, serum albu-
min (SAlb), or serum cholesterol (SChol) in patients who neck mass after only 6 months of treatment with MMF
and a total 30 months of prednisone. Biopsy disclosedincreased their dose of ACEi/AIIRa or HMG CoA re-
ductase inhibitor as compared with those who did not. Hodgkin’s lymphoma. Both lymphoma and nephrotic
proteinuria remitted completely with chemotherapy.
Minimal change disease One patient (#6) was MMF resistant.
The 7 patients with MCD had a median (range) age
Focal segmental glomerulosclerosisof 41 (23 to 74) years, 3 were male, 5 were Caucasian,
and 2 were African-American. Five of 7 patients were The 18 patients with FSGS had a median (range) age
of 37 (16 to 65) years, 66.7% were male, 13 (72.2%)nephrotic in the setting of a normal serum creatinine.
Baseline Up/c and SCr was 4.6 (0.1 to 6.0) and 1.0 (0.6 were Caucasian, 4 (22.2%) were African American and
1 (5.6%) was Asian. Quantitation of proteinuria was notto 1.7) mg/dL. The indication for MMF treatment was
steroid  CsA dependence in each, and 6 of 7 received available in 1 patient. At study entry the Up/c and SCr
values were 2.7 (0.1 to 20.3) and 1.85 (0.6 to 6.1) mg/dL,some form of concomitant steroid treatment. With the
exception of patients #2 and #4, the steroid and its dose respectively. Twelve of 18 (66.7%) patients had renal
insufficiency and 9 of 17 (52.9%) had nephrotic protein-were those in place prior to MMF.
Overall, 3 of 5 initially nephrotic patients (#1, 2, 4) uria despite ACEi/AIIRa therapy in 7 of 9. Indications
for MMF treatment included steroid resistance or ster-had complete remissions in proteinuria by the end of
the study. Change in Up/c with MMF treatment was91.4 oid  CsA dependency and/or progressive (sometimes
rapidly deteriorating) renal insufficiency.(98.0 to 9.0)%, P  0.05. In 2 of these (#2 and #4),
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Table 3. Mean and median values Up/c, serum albumin, serum cholesterol, mean arterial pressure, serum creatinine, and 100/serum creatinine
in the overall group and subgroups of primary glomerulopathies before and at the end of MMF treatment
Pre-MMF Post MMF
Mean Median Mean Median
N (x¯SD) (range) (x¯SD) (range) P
Overall group
Up/c 45 5.6 (4.7) 4.7 (.1, 20.3) 2.4 (3.0) 1.1 (0.1, 14.3) 0.001
Serum albumina 41 3.3 (0.96) 3.4 (1.4, 4.6) 3.9 (0.7) 4.1 (1.7, 4.8) 0.001
Serum cholesterolb 30 307.6 (139.0) 270 (148, 795) 219.9 (42.4) 220.0 (140, 309) 0.001
Mean arterial pressurec 41 99.7 (13.0) 100.0 (72.7, 130.0) 94.2 (10.3) 94.0 (73.3, 111.3) 0.008
Serum creatinine 46 1.8 (1.2) 1.3 (0.6, 6.1) 1.8 (1.4) 1.2 (0.5, 6.5) 0.39
100/serum creatinine 46 77.5 (39.8) 76.9 (16.4, 166.7) 85.0 (46.5) 83.3 (15.4, 200) 0.03
MCD
Up/c 7 4.1 (2.2) 4.6 (0.1, 6.0) 1.3 (2.2) 0.1 (0.1, 5.8) 0.05
Serum albumin 6 3.2 (1.3) 3.5 (1.4, 4.6) 3.9 (1.1) 4.2 (1.7, 4.6) 0.14
Serum cholesterol 3 274.5 (78.0) 258.5 (204, 426) 233 (25.4) 241 (205, 254) 0.66
Mean arterial pressure 6 93.6 (10.9) 93.3 (78.0, 110.0) 93.8 (13.4) 97.3 (73, 111) 0.89
Serum creatinine 7 1.07 (0.35) 1.0 (0.6, 1.7) 1.0 (0.3) 0.9 (0.7, 1.6) 0.20
100/serum creatinine 7 102.6 (35.0) 100.0 (58.8, 166.7) 108.7 (31.2) 111.1 (62.5, 142.9) 0.47
FSGS
Up/c 17 4.7 (5.1) 2.7 (0.1, 20.3) 2.2 (2.5) 0.8 (0.1, 8.2) 0.001
Serum albumin 17 3.4 (1.1) 3.7 (1.4, 4.6) 4.1 (0.6) 4.2 (2.7, 4.8) 0.01
Serum cholesterol 14 301.2 (175.7) 223 (148, 795) 203.9 (46.0) 187.5 (140, 309) 0.002
Mean arterial pressure 16 101.7 (12.0) 100.0 (77.3, 130.0) 91.9 (10.6) 92.0 (73.3, 109.3) 0.02
Serum creatinine 18 2.3 (1.5) 1.9 (0.6, 6.1) 2.5 (1.9) 2.2 (0.6, 6.5) 0.25
100/serum creatinine 18 66.5 (43.8) 54.4 (16.4, 166.7) 69.5 (50.8) 46.7 (15.4, 166.7) 0.93
MN
Up/c 17 7.7 (4.8) 7.3 (0.1, 18.5) 3.4 (3.8) 1.5 (0.1, 14.3) 0.001
Serum albumin 14 2.96 (0.66) 2.95 (2.10, 4.50) 3.5 (0.6) 3.6 (2.2, 4.6) 0.006
Serum cholesterol 11 334.9 (126.9) 312 (168, 623.0) 235.1 (40.0) 222 (179, 301) 0.05
Mean arterial pressure 15 99.4 (15.6) 97.3 (72.7, 130.0) 94.6 (9.5) 93.3 (80.0, 110.0) 0.14
Serum creatinine 17 1.5 (0.8) 1.1 (0.7, 3.5) 1.3 (0.7) 1.1 (0.5, 3.2) 0.03
100/serum creatinine 17 83.7 (34.7) 90.9 (28.6, 142.9) 97.9 (45) 90.9 (31.3, 200) 0.01
Abbreviations are: N, patient number; P, P values are calculated using the Wilcoxon signed-ranks test.
a Units in g/dL
b Units in mg/dL
c Units in mm Hg
Table 4. Change in serum creatinine
Pre-treatment Post-treatment P value (Wilcoxon
median (range) median (range) signed-ranks test)
Serum creatinine mg/dL 1.3 (0.6, 6.1) 1.2 (0.5, 6.5) 0.492
100/serum creatinine 76.9 (16.4, 166.7) 83.3 (15.4, 200) 0.027
4-variable simplified MDRD GFR
mL/min/1.73 m2 59.4 (11.4, 191.0) 67.3 (10.3, 191.0) 0.032
100/serum creatinine and estimated GFR using the four-variable simplified MDRD equation.
Twelve of 18 initially received concomitant steroid their proteinuria of 5 and 10%. In the 9 patients with
nephrotic range proteinuria, Up/c pretreatment was 7.5treatment; in 8 of those 12, the drug and its dose were
the same as those prior to MMF and, in 4, steroids were (2.7 to 20.3) and decreased to 3.9 (0.1 to 8.2) post-therapy
(P  0.008). One nephrotic patient (#13) experienced ainitiated at the same time as MMF in a previously de-
scribed protocol [1]. MMF was used as the only immuno- complete remission that has been sustained over 11
months following discontinuation of MMF. The magni-suppressive medication in the other 6 patients.
The Up/c decreased by a median of 48%, being 0.8 tude (Up/c) for the responses in proteinuria in the ne-
phrotic FSGS patients is illustrated in Figure 2. There(0.1 to 8.2) at the end of the MMF treatment period
(P 0.001; Table 2). Two patients (#13, #15)—including was a significant reduction in SChol and in the MAP, to-
gether with a significant improvement in SAlb levels (Ta-one from the nephrotic group—had a complete remis-
sion of proteinuria; 6 patients (35.3%)—including 4 from ble 2).
There was no significant change in serum creatininethe nephrotic group—had a partial remission; and 2 pa-
tients (11.1%)—both non-nephrotic—had an increase in in the FSGS patients as a group over the study period;
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Fig. 2. Up/c at initiation and at the end of the
MMF treatment period in individual ne-
phrotic FSGS patients. # is the patient identi-
fication number in Table 1. mo  months of
MMF therapy.
renal insufficiency resolved in 1 of 12 cases, with no cases patients increased their dose, 7 patients remained on a
constant dose, and 6 decreased their dose of ACEi/developing de-novo renal insufficiency during MMF
therapy. Two (#13, 18) of 12 patients with renal insuffi- AIIRa over the course of the study. There was no signifi-
cant association between change in ACEi/AIIRa statusciency (SCr 1.7 and 3.8 mg/dL, respectively) manifested
improved excretory renal function. One of those two and change in proteinuria, SCr or MAP. Of the 14 patients
receiving an HMG CoA reductase inhibitor, 4 increased(#18) with rapidly deteriorating renal function mani-
fested a marked slowing of the rate of progression over their dose, 7 stayed on a constant dose, and 3 decreased
their dose, with no significant independent associationthe ensuing 40 weeks. In 3 patients (#14, 17, 25), renal
function continued to deteriorate over 5 to 22 months. between the change in medication use and the improve-
ment in serum cholesterol level.One of these patients (#25) had collapsing FSGS on
biopsy in a solitary kidney. In the other 7 patients (#8, Of 12 patients initially receiving concomitant steroid
therapy, it was withdrawn completely without relapse in9, 10, 15, 20, 23, 24), renal function stabilized over 4 to
12 months. 8. One patient relapsed and steroid was resumed, and 3
patients continued on low dose (MP 12 mg/day) treat-Of the 17 patients receiving either ACEi or AIIRa, 4
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ment. Two of the 3 CsA dependent patients and 1 AZA was successfully achieved in the majority (14 of 15,
dependent patient did not require restarting of these 93.3%) of patients with steroid or CsA dependency. In
medications. MMF was discontinued in one patient (#20) one patient (#37) who was both steroid and CTX depen-
because of reversible mild increases in serum transami- dent, MMF treatment permitted a reduction in steroid
nase levels with concomitant alcohol use. (The patient dose and CTX was stopped shortly after starting MMF.
has subsequently been retreated, with normal liver en- MMF dependency was observed in 4 patients (#26, 27,
zymes, after abstinence from alcohol.) 34, and 36). One patient (#28) developed mild reversible
leukopenia. Three patients had MMF discontinued. One
Membranous nephropathy patient (#36) developed severe erosive gastritis, one pa-
The 17 patients with MN had a median (range) age tient (#27) developed pneumonia, and one patient (#28)
of 54 (30 to 75) years, 58.8% were male, 14 (82.4%) developed squamous cell cancer of the arm with prior
were Caucasian, 2 (11.8%) were African-American and and continued steroid and CsA treatment.
1 (5.9%) was Asian. Fifteen patients (88.2%) had ne-
IgANphrotic range proteinuria and six (35.3%) had renal in-
sufficiency. At baseline, Up/c and SCr were 7.3 (0.1 to 18.5) Two of the 3 patients had renal insufficiency and one
and 1.1 (0.7 to 3.5) mg/dL, respectively. Indications for had, in addition, nephrotic proteinuria. The other patient
MMF treatment included steroid (11/17)  CsA (4/17) (#44) was steroid dependent and had suffered serious
or CTX (1/17) dependency, steroid or CsA resistance, complications from steroid therapy. Patient #43 experi-
steroid or CsA intolerance, suboptimal response to CsA, enced substantial improvement in excretory renal func-
and progressive renal insufficiency. Three patients re- tion and a partial remission in proteinuria. He relapsed
ceived MMF monotherapy. after 3 months, however, when MMF was discontinued
In all patients with membranous nephropathy, the me- while he underwent tonsillectomy, but he responded
dian percent reduction in Up/c was 61.1%, being 1.5 (0.1 again following resumption of MMF. Two patients (#43
to 14.3) at the end of MMF treatment period (P 0.001). and 45) showed improvement in renal function while
The magnitude for the responses in proteinuria to MMF receiving MMF. All three patients had been on fish oil
in the nephrotic MN patients is illustrated in Figure 3. prior to and during MMF therapy.
In the 15 patients with nephrotic range proteinuria, Up/c
was 7.8 (3.6 to 18.5) pretreatment and was 2.3 (0.1 to MPGN
14.3) post-treatment (P  0.001). Two patients (13.3%),
Patient #46 had both renal insufficiency and nephrotic
both of whom who were nephrotic, achieved a complete
proteinuria. Excretory renal function transiently im-remission; 8 patients (60%), all of whom were nephrotic,
proved until gastrointestinal symptoms required a dos-achieved a partial remission; and 2 patients (13.3%),
age reduction. He did, however, experience a substantialincluding 1 nephrotic, had increased proteinuria. Eight
partial remission in proteinuria.of the 15 (53.3%) nephrotic patients improved to sub-
nephrotic proteinuria with treatment. Two patients re- Steroid- and/or CsA-resistant nephrotic patients
lapsed after MMF was stopped, and they both responded
There were 10 patients (#17, 19, 28, 29, 30, 31, 33, 36,to retreatment.
40, 41) with nephrotic proteinuria who had previouslyWith MMF treatment there was no change in median
failed to respond to steroids (N  7) or CsA (N  2);serum creatinine or mean arterial pressure. There were
one (#29) had failed to respond to both. Of these resistantsignificant improvements in serum albumin and choles-
patients, 2 had FSGS (#17, 19) and the remainder hadterol (Table 2). Three of 6 patients (#27, 29, 33) with renal
MN. One MN patient (#31) had a complete and sustainedinsufficiency experienced substantial improvement in ex-
(more than 2 years after MMF stopped) remission. Incretory renal function. One patient (#37) had an increase
these 10 patients, Up/c decreased significantly from 7.2in serum creatinine of 10% after 17 months of treatment.
(2.2, 20.3) pre MMF to 1.9 (0.1, 7.2) with MMF treatmentOf the 14 patients receiving ACEi or AIIRa, 5 patients
(P  0.005). Three of the patients had remained on aincreased, 8 patients remained on a constant dose, and
constant dose of ACEi/AIIRa, 4 on an increased dose,1 decreased their dose over the course of the study.
and 3 on a decreased dose; 5 had remained on a constantThere was no significant association between change in
dose of HMG CoA reductase inhibitor with 3 reducingACEi/AIIRa status and change in the above clinical pa-
their dose and 2 increasing their dose over the courserameters. Of the 15 patients receiving HMG CoA reduc-
of follow-up.tase inhibitors, 5 increased, 8 stayed on a constant dose,
There was, in addition, significant improvement in SAlband 2 decreased their dose of lipid lowering medication,
and SChol. Serum albumin increased from 2.6 (1.4, 4.5)with no significant independent association between the
g/dL to 3.8 (2.9, 4.6) g/dL (P  0.01) at the end of treat-change in medication use and improvement in SChol level.
Progressive steroid withdrawal and CsA withdrawal ment. Serum cholesterol post-MMF was 212 (160, 225)
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Fig. 3. Up/c at initiation and at the end of MMF
treatment in individual nephrotic membra-
nous nephropathy patients. # is the patient
identification number in Table 1. momonths
of MMF therapy.
mg/dL as compared to the pre-MMF value of 348 (202, 3.95 to 4.15 g/dL (P 0.09), serum cholesterol decreased
from 243 to 205 mg/dL (P 0.011), and MAP decreased795) mg/dL (P  0.01).
from 106.6 to 98.7 mm Hg. Three patients (#9, 20, 27)
MMF MONOTHERAPY required MMF retreatment because of relapse.
Twelve patients (#1, 9, 10, 12, 15, 20, 24, 27, 30, 40,
RAPIDLY INCREASING SCr45, 46) were treated with MMF alone. One patient had
minimal change disease, 6 had focal segmental glomeru- Among the patients reported here, there were 8 who
not only had renal insufficiency, but who were manifest-losclerosis, and 3 had membranous nephropathy. One
had IgA nephropathy and 1 had membranoproliferative ing a relatively rapid progressive deterioration in renal
function prior to the initiation of MMF treatment (SCrglomerulonephritis (hepatitis C negative PCR). There
were no Up/c data available for patient #9. Up/c decreased rising 20% within 40 weeks of initiating MMF treat-
ment). The changes in SCr in these 8 patients 40 weeksfrom 4.0 to 0.8 (P 0.005) and SCr values were 1.9 mg/dL
at the start of MMF therapy to 1.7 mg/dL (P  1.0) at prior to, at the start of, MMF, then 40 weeks following
initiation of MMF treatment, are shown in Figure 4. Sixthe end of MMF therapy. Serum albumin increased from
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Fig. 4. Patients with rapidly rising serum cre-
atinine. Eight patients demonstrated a 20%
increase in the serum creatinine 40 weeks
prior to MMF therapy. The serum creatinines
of these 8 patients are shown prior to and after
MMF therapy started.
of 8 (#8, 9, 18, 27, 36, 43) manifested either stabilization the majority of, but not all, treated patients experienced
short to intermediate term benefit from MMF therapy,or improvement in excretory renal function with treat-
ment. The subsequent decrease in some patients was whether in terms of markedly decreased cumulative ste-
roid exposure, complete or partial remission of nephroticimpressive, and in none of these 8 patients was there
proteinuria or in favorable modifications of the rate ofany evidence of confounding conditions such as volume
deterioration in renal function. Unfortunately, it is notdepletion, heart failure, obstructive uropathy, or expo-
possible to anticipate the individual response to MMFsure to contrast agents, nephrotoxic agents or drugs
in advance of therapy. Patients’ response to therapy doeswhich might cause impaired glomerular function or acute
not appear to be related to the degree of proteinuria.interstitial nephritis, the correction of which could ex-
Interestingly, twelve patients were treated with MMFplain the changes observed.
alone and showed a similar decrease in urine protein
ESTIMATE OF GLOMERULAR FILTRATION excretion, increase in serum albumin, decrease in choles-
RATE, TOTAL STUDY GROUP terol and MAP. Not surprisingly, it is now apparent that
some patients will fail to respond to MMF and that,Estimated GFR significantly improved over the study
similar to the situation with CsA, a proportion of respon-period whether estimated by 100 multiplied by the recip-
sive patients will be found to be MMF dependent androcal of serum creatinine, or the four-variable simplified
relapse when treatment is discontinued.MDRD formula (Table 4).
It is assumed that MMF is effective in the treatment
of responsive patients as a result of a combination of its
DISCUSSION immunosuppressive properties and its other mechanisms
The results presented here largely confirm and sub- of action. Mycophenolic acid (MPA), the pharmacologi-
stantially extend our initial observations regarding the cally active metabolite of MMF, inhibits both T and B
efficacy of MMF for the treatment of glomerular dis- lymphocyte proliferation, B lymphocyte antibody pro-
duction, as well as the glycosylation and expression ofeases. We have not included our additional experiences
in patients with lupus nephritis or vasculitis, but have adhesion molecules [21–26]. In addition, MPA has been
shown to inhibit vascular smooth muscle cell [22] andelected in this report to focus on our experience with
patients with primary glomerulopathies, predominantly mesangial cell proliferation [11], to be a selective inhibi-
tor of inducible nitric oxide synthase [27], and to inducerelapsing MCD, FSGS, and MN. The results indicate that
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apoptosis in activated T cells [28]. One or another, or sparing efficacy of MMF is also illustrated in a case report
by Chandra, Susin and Abitbol, in which a 21-year-olda combination of these actions could account for the
observed amelioration of various experimental models man with an 18 year history of severe relapsing nephrotic
syndrome from FSGS, despite multimodal treatment,of glomerular disease, including active [10] and passive
Heymann nephritis, hyperfiltration injury in remnant and complicated by severe steroid toxicity, was subse-
quently maintained in remission with MMF monother-kidney [5–9], mesangial proliferative nephritis [11, 12],
and murine lupus nephritis [13–15] (abstracts; Heering apy, allowing resolution of all steroid side effects [17].
Since the majority of our nephrotic FSGS patients hadet al, J Am Soc Nephrol 9:456A-7A, 1998; Wen-Ling et
al, J Am Soc Nephrol 9:496A, 1998). These same mecha- concomitant renal insufficiency, it is not surprising that
only one experienced a complete remission. It is tenta-nisms are likely to be operative in the amelioration of the
inflammation and/or structural remodeling characteristic tively encouraging that the one complete remission and
two partial remissions have been sustained without ste-of human glomerular diseases.
Steroid dependent MCD is problematic because of roids after MMF was discontinued. Stabilization, and es-
pecially improvement (albeit modest), of excretory renalthe need for repeated moderate-to-high–dose steroid ex-
posure and/or long-term cumulative steroid exposure. In function in several patients was particularly noteworthy.
The generally favorable responses of nephrotic pro-contrast to children, adults with MCD are more likely
to be steroid resistant or steroid dependent. Historically, teinuria in our cohort of FSGS patients is not felt to
represent a realistic expectation for the treatment of athe treatment of relapsing or resistant patients has been
with either CsA or a cytotoxic drug. Unfortunately, ste- broader spectrum of patients, however, especially those
previously resistant to other treatment strategies. In-roid resistance also often predicts resistance to these
second line drugs. In addition, CsA dependency has of- deed, Radhakrishnan et al reported results for 11 pre-
viously steroid and either CsA or CTX resistant patients,ten been the trade-off for steroid dependency, and cyto-
toxic drugs carry their well-known potential toxicities. who remained nephrotic after MMF treatment, despite
a significant decrease in proteinuria (abstract; Radha-The potential role for MMF in steroid CsA dependent
MCD is that of an effective steroid sparing agent without krishnan et al, J Am Soc Nephrol 10:114A, 1999).
Membranous nephropathy is often complicated by ne-the potential adverse renal, hemodynamic, and meta-
bolic effects of CsA. If discontinuation of MMF after 6 phrotic syndrome with moderate to severe edema/ana-
sarca, requiring intensive diuretic therapy. Treatmentto 12 months of treatment is followed by a relapse, our
results indicate that retreatment of relapse will likely be considerations are quite controversial, thereby generat-
ing an expanding literature. In our experience, such pa-effective, and the treating physician always has the op-
tion of proceeding to cytotoxic therapy. Alternatively, tients generally respond suboptimally, if at all, to steroids,
and those who do often manifest steroid dependency.the results in patient #1 suggest that a more prolonged
course of treatment with MMF may ultimately lead to CsA has been effective, but usually associated with CsA
dependency.a sustained complete remission after stopping MMF.
Focal segmental glomerulosclerosis is especially sig- We have found MMF to be very effective in ameliorat-
ing nephrotic proteinuria and its complications in MN,nificant because it has become the leading cause of ne-
phrotic syndrome in adults and, more importantly, be- with responses in our experience equivalent to those
achieved with CsA. Although all patients experiencedcause of its propensity to progress to end-stage renal
disease (ESRD). Nephrotic proteinuria and decreased marked clinical improvement, complete remissions were
few (2 of 15, 13.3%), and it became apparent that someexcretory renal function are independent risk factors for
progression to ESRD. Induction of complete, and even patients would manifest MMF dependency or relapse
with steroid withdrawal despite continued MMF therapy.partial, remission of nephrotic proteinuria has been
shown to favorably modify the renal prognosis in FSGS Nevertheless, MMF had major steroid-sparing effects in
the majority of patients. The substantial improvement[29]. High-dose and prolonged steroid treatment has
been found to be effective for induction of remissions in excretory renal function in several MN patients in our
cohort was again noteworthy. The results in our nephroticin nephrotic proteinuria in substantial proportions of
affected patients [30]. Although generally satisfactorily MN patients previously resistant to steroids (and CsA in
one) are similar to the results in some of the patientstolerated, the downside of such treatment includes both
the total cumulative steroid exposure and steroid intoler- recently reported by Miller et al [18]. In their 16 MN
patients previously resistant to steroids, CsA, or cytotoxicance in a few patients.
Not only was MMF treatment effective in inducing drugs, they saw partial remissions in 2 patients, and a
50% reduction in the magnitude of proteinuria in 6 othersubstantial remissions of proteinuria in the majority of
nephrotic FSGS patients reported here (including 1 pre- patients over a six-month period of MMF treatment.
The results of MMF treatment in the patients withviously steroid-resistant), it was also found to have major
steroid-sparing effects. The potential beneficial steroid- IgAN and MPGN were similar to those in the patients
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with FSGS and MN. Therefore, MMF may also provide associated with protracted exposure to steroids and/or
calcineurin inhibitors. Details of patients completing atherapeutic benefit for selected patients with diseases
other than those associated with the so-called primary course of MMF therapy are given in Table 2.
In general, MMF was very well tolerated in the dosesnephrotic syndrome. This notion is compatible with the
reports of the efficacy of MMF in patients with lupus used in these patients. Adverse effects from MMF were
limited and similar to those identified in organ transplantnephritis [1–4] and other systemic vasculitides [16, 19].
Median serum creatinine did not change pre- and post- recipients. Most common were gastrointestinal com-
plaints of dyspepsia and/or loose stools. With one excep-MMF treatment in the overall group, however, more
precise estimates of glomerular filtration rate revealed tion, these were mild to moderate in severity and re-
solved either spontaneously or with H2 blocker therapy,a statistically and clinically significant improvement in
excretory function in the overall group during MMF proton pump inhibitors, or MMF dosage adjustments.
Mild leukopenia occurred in two patients, one with nor-treatment. Mean arterial pressure decreased significantly
for the group as a whole. Although these changes may mal and the other with impaired renal function; both
resolved rapidly with dosage adjustment and MMF ther-have been due to increases in antihypertensive medica-
tions in a minority of patients, we feel the major effect on apy was continued. No other hematologic abnormalities
were attributable to MMF. One patient developed aMAP was secondary to improvement in the glomerular
disease with MMF therapy. reversible increase in serum transaminase levels with
concomitant alcohol use, which prompted discontinua-As with any form of empiric treatment undertaken
in the absence of established guidelines, the dose and tion. The patient has been retreated with MMF for more
than four months after abstinence from alcohol, withoutduration of MMF treatment in this cohort were variable
among patients. Therefore, this report can only provide elevation of liver function tests.
The most serious potential complication of MMF wassuggestions for consideration regarding these parame-
ters. Our preliminary observations [1] and subsequent the manifestation of Hodgkin’s lymphoma in one patient
with MCD after five months of treatment. Lymphomaexperience reported here continue to suggest that for
individuals of average stature/build and normal or mildly has been reported in organ transplant recipients receiv-
ing MMF along with steroids and calcineurin inhibitorsimpaired renal function, there is a threshold dose of 1.5
g/day for efficacy and that an appropriate response can [32]. Although the development of lymphoproliferative
disease is a well-recognized complication of intensive,be anticipated with total daily doses of 1.5 to 2.0 g.
Individuals of small stature or those with moderately to high dose and/or prolonged multidrug immunosuppres-
sion, its development seems quite unusual after only sixseverely impaired renal function may respond to 1.0 to
1.5 g/day. We suggest caution and careful monitoring months of MMF treatment in our case. In addition, it is
well recognized that MCD can be the initial paraneoplas-in patients with advanced renal insufficiency, given the
known alterations in MPA pharmacokinetics under such tic manifestation of underlying Hodgkin’s lymphoma,
and, compatible with the latter situation, our patientcircumstances [31]. On the other hand, dosing may be
suboptimal at 2.0 g/day in large patients or in African experienced a complete remission of both lymphoma
and nephrotic proteinuria with chemotherapy. Neverthe-American patients. We suspect that optimal dosing in
all patients will not be achieved until measurements of less, it is not possible to exclude a cause and effect rela-
tionship between the MMF treatment and the lymphomaserum MPA levels or activity are clinically available.
The issue of optimal duration of therapy also remains at this time.
The authors acknowledge the limitations inherent inunresolved. There were 17 patients treated for 3 to 6
months (#1, 3, 4, 6, 7, 10, 12, 20, 21, 22, 23, 25, 26, 34, this report. First, and foremost, the results are not those
of a controlled clinical trial with randomization to receive36, 43, 45); 18 patients treated for 6 to 12 months (#5,
8, 9, 11, 13, 15, 18, 19, 24, 27, 30, 31, 38, 39, 40, 41, 42, or not receive concomitant steroid therapy according to
prescribed stratified dosing regimens. Thus, issues such46); 8 patients treated for 12 to 24 months (#14, 16,
17, 28, 33, 35, 37, 44); and 3 patients treated 24 months as how often, and under what circumstances, MMF mo-
notherapy might be effective, and what dosage regimen(#2, 29, 32). In patients who respond dramatically within
three months, consideration might be given to an attempt of concomitant steroid therapy would achieve optimal
results, remain unclear. Second, although the responsesto discontinue treatment after six months. In those who
relapse and in those whose maximal response takes three in our African American patients were equivalent to
those in Caucasian patients, the former represented onlyto six months to achieve, we extend the treatment period
to at least one year. It is apparent that for some MMF 17.4% of our cohort. Thus, our results may not be appli-
cable to a larger, more representative group of Africandependent patients, treatment may have to be prolonged
well beyond one year to maintain the desired response. American glomerular disease patients, particularly those
with FSGS. Third, the proportion of steroid-resistantIf the clinical situation warrants such an approach, at
least the patient will be spared the potential problems patients was relatively small; therefore, the generally
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mycophenolate mofetil and losartan therapy arrests establishedfavorable responses seen here may not be applicable to
injury in the remnant kidney. J Am Soc Nephrol 11:283–290, 2000
a larger group of such affected patients. 9. Badid C, Vincent M, McGregor B, et al: Mycophenolate mofetil
reduces myofibroblast infiltration and collagen III deposition inIn summary, albeit non-randomized and anecdotal in
rat remnant kidney. Kidney Int 58:51–61, 2000nature, the results reported here in a substantial number
10. Penny MJ, Boyd RA, Hall BM: Mycophenolate mofetil prevents
of patients, firmly establish the short-term efficacy of the induction of active Heymann nephritis: Association with Th2
cytokine inhibition. J Am Soc Nephrol 9:2272–2282, 1998MMF in the treatment of primary glomerular diseases,
11. Hauser IA, Renders L, Radeke HH, et al: Mycophenolate mofetilin particular relapsing MCD, FSGS, and MN. As with
inhibits rat and human mesangial cell proliferation by guanosine
all novel treatment strategies, however, the proper role depletion. Nephrol Dial Transplant 14:58–63, 1999
12. Ziswiler R, Steinmann-Niggli K, Kappeler A, et al: Mycophe-for MMF in the management of glomerular diseases can
nolic acid: A new approach to the therapy of experimental mesan-only be determined from prospective, well-designed clin- gial proliferative glomerulonephritis. J Am Soc Nephrol 9:2055–
ical trials in appropriately stratified, large patient co- 2066, 1998
13. Corna D, Morigi M, Facchinetti D, et al: Mycophenolate mofetilhorts. Although the clinical improvement in the majority
limits renal damage and prolongs life in murine lupus autoimmuneof patients occurred with the combination of MMF with disease. Kidney Int 51:1583–1589, 1997
variable doses of steroid, our results demonstrate that 14. McMurray RW, Elbourne KB, Lagoo A, Lal S: Mycophenolate
mofetil suppresses autoimmunity and mortality in the femaleMMF has major steroid-sparing effects and can even be
NZB x NZW F1 mouse model of systemic lupus erythematosus.
effective as monotherapy. Given the lack of nephrotoxic- J Rheumatol 25:2364–2370, 1998
15. Van Bruggen MCJ, Walgreen B, Rijke TPM, Berden JHM:ity and adverse hemodynamic and metabolic effects,
Attenuation of murine lupus nephritis by mycophenolate mofetil.MMF represents a suitable alternative to the calcineurin-
J Am Soc Nephrol 9:1407–1415, 1998
inhibitors as adjuvant treatment for many patients, espe- 16. Nowack R, Birck R, van der Wonde FJ: Mycophenolate mofetil
for systemic vasculitis and IgA nephropathy. (letter) Lancet 349:cially those with progressive renal insufficiency. In the
774, 1997doses used in this report, MMF is generally well tolerated
17. Chandra M, Susin M, Abitbol C: Remission of relapsing child-
with few serious side effects, but the risk of lymphoproli- hood nephrotic syndrome with mycophenolate mofetil. Pediatr
Nephrol 14:224–226, 2000ferative disease or other long-term adverse sequelae re-
18. Miller G, Zimmerman R, III, Radhakrishnan J, Appel G: Usemains indeterminate at this time. of mycophenolate mofetil in resistant membranous nephropathy.
Am J Kidney Dis 36:250–256, 2000
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